靶向肿瘤细胞特异性αvβ6整合素表达的食管癌PET/CT显像
该研究评估αvβ6整合素作为食管癌诊疗一体化靶点的潜力。免疫组化分析100例食管鳞状细胞癌(ESCC)患者的306份标本,99%为β6整合素阳性。临床前及一例患者Ga-68-D0103 PET/CT显示肿瘤高摄取和滞留,作者认为αvβ6整合素PET/CT可能在再分期和治疗指导中发挥作用。
要点
- 免疫组化显示99%的ESCC病例为β6整合素阳性,48%强表达、31%中等表达、20%低表达,与肿瘤分级无关。
- Ga-68-D0103在H2009荷瘤鼠中肿瘤/血液比值30、90、180分钟分别为6.8、37、124。
- 临床一例ESCC患者Ga-68-D0103 PET/CT示原发灶SUVmax从15分钟9.0升至104分钟11.3,淋巴结转移灶SUVmax从19.5升至28.3。
核心结论
- 肿瘤细胞膜β6整合素高表达频率(99%)和密度提示αvβ6整合素是ESCC的诊疗一体化靶点。
- 作者认为αvβ6整合素PET/CT显像可能在该癌种的再分期和治疗指导中发挥作用。
- 肿瘤滞留延长提示,当标记镥-177、铽-161或锕-225等核素时,αvβ6整合素靶向放射性药物具有治疗潜力。
研究设计与样本
- 免疫组化分析100例患者共306份人ESCC标本的膜性β6整合素(ITGB6)表达,其中G1、G2、G3、G4分别为1、37、58、4例。
- Ga-68标记D0103在临床前实验手动进行,临床应用全自动进行。
- 临床前在荷H2009(αvβ6阳性)或MDA-MB-231(αvβ6阴性)癌细胞的SCID小鼠皮下异种移植瘤中进行离体生物分布(注射后10、30、90、180分钟)和PET显像(注射后30、90、180分钟),有或无明胶琥珀酰化(4%琥珀酰化明胶)共注射。
- 一例68岁女性、体重115 kg、近端G2 ESCC的2型糖尿病患者接受193 MBq Ga-68-D0103 PET/CT,于注射后15、45、90、104分钟显像。
主要发现
- 99%的ESCC病例免疫组化为β6整合素阳性,其中48%强、31%中等、20%低ITGB6表达,与肿瘤分级无相关性。
- H2009荷瘤鼠注射后30、90、180分钟肿瘤/血液比值分别为6.8、37、124,肿瘤/肌肉比值分别为12、14、36,肿瘤/肝脏比值分别为10、17、14,肿瘤/胰腺比值分别为20、47、56。
- 共注射明胶琥珀酰化不改变肿瘤摄取,但使注射后90分钟肾脏摄取降低89%(从178%iA/g降至19.1%iA/g),肿瘤/肾脏比值提高8.7倍。
- H2009荷瘤鼠µPET显像证实注射后30分钟即出现高肿瘤摄取和低背景。
- αvβ6阴性MDA-MB-231小鼠的阻断生物分布和µPET证实靶点特异性。
临床怎么用
- 作者认为αvβ6整合素PET/CT显像可能在该癌种的再分期和治疗指导中发挥作用。
- 作者指出肿瘤滞留延长提示αvβ6整合素靶向放射性药物在标记镥-177、铽-161或锕-225等核素时具有治疗潜力。
局限性
- 临床部分仅报告一例患者(68岁女性、体重115 kg、近端G2 ESCC的2型糖尿病患者)的Ga-68-D0103 PET/CT结果,原文未报告其他临床病例。
- 原文结论中使用「may adopt a role」「indicates a therapeutic potential」等限定表述,未报告进一步验证结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the potential of αvβ6-integrin as a theranostic target in esophageal cancer. METHODS: Membranous β6-integrin (ITGB6) expression was analyzed in 306 specimens of human esophageal squamous cell carcinoma (ESCC) obtained by immunohistochemistry (IHC) from 100 patient cases (1, 37, 58, and 4 of grade G1, G2, G3, and G4, respectively). Ga-68 labeling of D0103 was done manually for preclinical experiments and fully automated for clinical application. Preclinical characterization of Ga-68-D0103 was performed in SCID mice bearing subcutaneous xenografts of H2009 (αvβ6-positive) or MDA-MB-231 (αvβ6-negative) carcinoma cell lines, by ex vivo biodistribution (10, 30, 90, and 180 min p.i) and PET imaging (30, 90, and 180 min p.i.)., without and with co-injection of gelofusine (4% succinylated gelatin). A patient with type-II diabetes (f, 68y, 115 kg) with proximal G2 ESCC was investigated by Ga-68-D0103 PET/CT (193 MBq) at 15, 45, 90, and 104 min p.i.. RESULTS: 99% of ESCC cases were found β6-integrin positive by IHC, of which 48%, 31%, and 20% showed strong, moderate, and low ITGB6 expression, respectively, with no correlation to tumor grade. Ex vivo biodistribution of Ga-68-D0103 in H2009 xenografted mice after 30, 90, and 180 min showed tumor-to-blood ratios of 6.8, 37, and 124, respectively; tumor-to-muscle ratios of 12, 14, and 36, respectively; tumor-to-liver ratios of 10, 17, and 14, respectively; and tumor-to-pancreas ratios of 20, 47, and 56, respectively. Co-administration of gelofusine did not change the tumor uptake but reduced the kidney uptake by 89% (from 178%iA/g to 19.1%iA/g, 90 min p.i.), resulting in an 8.7-fold higher tumor/kidney ratio. µPET imaging in H2009 xenografted mice confirmed a high tumor uptake and low background already 30 min p.i.. Blockade biodistribution and µPET in αvβ6-(-) MDA-MB-231 mice demonstrated target specificity. Clinical PET/CT of a patient with ESCC showed increasing tracer uptake over time in the primary tumor (SUVmax 9.0 and 11.3 at 15 and 104 min p.i., respectively) and in a lymph node metastasis (SUVmax 19.5 and 28.3, respectively), and a decreasing blood pool activity (SUVmean 2.75 and 0.98, respectively). CONCLUSIONS: High (99%) membranous expression frequency and density on tumor cells underscores the potential of αvβ6-integrin as a theranostic target in ESCC, suggesting that αvβ6-integrin PET/CT imaging may adopt a role in re-staging and therapy guidance in this cancer type. The prolonged tumor retention furthermore indicates a therapeutic potential of αvβ6-integrin targeted radiopharmaceuticals when labeled with radionuclides such as lutetium-177, terbium-161, or actinium-225.
引用
- Bendová KD, Groll T, Neužilová B, et al. PET/CT imaging of esophageal cancer targeting tumor cell specific αvβ6-integrin expression. Eur J Nucl Med Mol Imaging. 2025. PMID: 40540027. doi:10.1007/s00259-025-07408-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。